Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 44 min ago
PreprintAll rights reservedbioRxiv

Domain-resolved epitope mapping of B7-H3-targeting VHH-Fcs defines isoform-selective binders for antibody-drug conjugate development

  • X. Fang
  • B. Chalopin
  • S. S. Gokturk
  • A. S. Bhagwani
  • M. Sudareva
  • R. Molkenbur
  • W. Tian
  • M. Feng
  • F. L. H. van Rijt
  • K. van Noort
  • J. Koelewijn
  • M. Chatziandreou
5 more authors
  • B. Zhang
  • J. H. M. Merks
  • C. Rossig
  • R. Meissner
  • C. Y. Janda1
  1. 1Princess Maxima Center for Pediatric Oncology
Read full textPDFDOICite

Related

  1. Targeting tumor-selective membrane-associated PCNA enables selective antibody-drug conjugate therapy.
    Muhammad Abu Ahmad, Nir Miriam Ungar-Malma, Alon Naumchik +11
    OncoimmunologyPeer-reviewedCC BY-NCFull textMedical imaging & radiologyEurope PMC
  2. 535 BC3195, a novel cadherin-3 targeting antibody drug conjugate, combined with pembrolizumab in patients with advanced solid malignancies: preliminary results from a phase I/II study (BC3195-103/G36)
    Yi-Long Wu, Hai-jun Guo, Chongrui Xu +5
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  3. Cell-resolved spatial mapping of antibody-drug conjugate targets in breast cancer.
    Yang Zhao, Zhixia Bai, Tao Li
    Translational oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  4. Quantitative Systems Pharmacology Model for Trop-2 Targeting Antibody-Drug Conjugate in Triple-Negative Breast Cancer
    S. Dogru, A. Suresh, E. P. Bowman +3
    bioRxivPreprintCC BY-NC-NDFull textPharmacology & toxicologybioRxiv
  5. Antibody-drug conjugate combination therapy targeting LGR5 and MET with different payloads enhances efficacy in preclinical colorectal cancer models
    S. Subramanian, P. C. High, C. Guernsey-Biddle +7
    bioRxivPreprintCC BY-NDFull textOncologybioRxiv

Cite

BibTeXRIS
BibTeX
@misc{fang2026domainresolved,
  title = {{Domain-resolved epitope mapping of B7-H3-targeting VHH-Fcs defines isoform-selective binders for antibody-drug conjugate development}},
  author = {X. Fang and B. Chalopin and S. S. Gokturk and A. S. Bhagwani and M. Sudareva and R. Molkenbur and W. Tian and M. Feng and F. L. H. van Rijt and K. van Noort and J. Koelewijn and M. Chatziandreou and B. Zhang and J. H. M. Merks and C. Rossig and R. Meissner and C. Y. Janda},
  howpublished = {bioRxiv},
  year = {2026},
  month = oct,
  doi = {10.64898/2026.10.16.759583},
  url = {https://www.biorxiv.org/content/10.64898/2026.10.16.759583v1},
}
RIS
TY  - UNPB
TI  - Domain-resolved epitope mapping of B7-H3-targeting VHH-Fcs defines isoform-selective binders for antibody-drug conjugate development
AU  - X. Fang
AU  - B. Chalopin
AU  - S. S. Gokturk
AU  - A. S. Bhagwani
AU  - M. Sudareva
AU  - R. Molkenbur
AU  - W. Tian
AU  - M. Feng
AU  - F. L. H. van Rijt
AU  - K. van Noort
AU  - J. Koelewijn
AU  - M. Chatziandreou
AU  - B. Zhang
AU  - J. H. M. Merks
AU  - C. Rossig
AU  - R. Meissner
AU  - C. Y. Janda
PY  - 2026
DA  - 2026/10/16
PB  - bioRxiv
DO  - 10.64898/2026.10.16.759583
UR  - https://www.biorxiv.org/content/10.64898/2026.10.16.759583v1
ER  -